7 unchanged sentences
Securities Litigation , No.
−Removed: 1:24-cv-12299, in its entirety, ruling in favor of the Company and the individual defendants, and denied the lead plaintiff's request for leave to amend.
+Added: 1:24-cv-12299, in its entirety, ruling in favor of the Company and the individual defendants, and denied the lead plaintiff's request for leave to amend his complaint.
The action was originally filed in September 2024 against the Company and certain of its executives and directors.
−Removed: The amended complaint, filed February 7, 2025 by the court-appointed lead plaintiff, alleged that Agenus, three of its current officers, and one member of its advisory board violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to the efficacy and commercial prospects of botensilimab and balstilimab.
+Added: The amended complaint, filed February 7, 2025 by the court-appointed lead plaintiff, alleged that Agenus, three of its current officers, and one member of its advisory board violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to the efficacy and commercial prospects of BOT and BAL.
The lead plaintiff sought to represent all persons who purchased or otherwise acquired Agenus securities between January 23, 2023 and July 17, 2024, and sought damages, interest, and an award of costs, including attorneys' fees.
−Removed: On April 15, 2026, the lead plaintiff filed a Notice of Appeal to the U.S.
−Removed: Court of Appeals for the First Circuit in a case captioned Olsen v.
−Removed: Agenus, Inc., et al., No.
−Removed: The First Circuit requires the parties to participate in a mandatory settlement conference, which is scheduled for May 26, 2026.
−Removed: The Company intends to vigorously defend the District Court's dismissal on appeal.
+Added: The lead plaintiff has appealed the Court's order to the U.S.
+Added: Court of Appeals for the First Circuit in the matter captioned Olsen v.
+Added: Agenus, Inc., et al.
+Added: Briefing in the appeal commenced in June 2026, and the lead plaintiff contends that the Court erred as a matter of law in dismissing the claims against the Company and Garo Armen.
+Added: The Company intends to vigorously defend the Court's dismissal order.
The Company has also been served with four derivative actions filed in the Court between November 2024 and January 2025 by purported stockholders.
−Removed: These actions name certain of the Company's executives and directors and allege that defendants made false or misleading statements and omissions of material fact related to the efficacy and commercial prospects of botensilimab and balstilimab.
+Added: These actions name certain of the Company's executives and directors and allege that defendants made false or misleading statements and omissions of material fact related to the efficacy and commercial prospects of BOT and BAL.
Plaintiffs seek an award of damages and an order directing the Company to reform and improve its corporate governance and internal procedures.
1 unchanged sentence
1:24-cv-12823 and stayed all deadlines pending future developments in the securities class action.
+Added: The Company is unable to estimate a range of loss, if any, that could result from an adverse outcome in these consolidated actions.
The Company is not currently a party to any other material legal proceedings.
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.